INSIGHTS ON DRUG DEVELOPMENT

• Rapid Walkaway Solution For Assessing Viability In Cancer Organoids

  Assess anti-cancer compounds' effects on organoid size and morphology with colorectal cancer organoids as well as discover automated imaging and viability assays to streamline drug screening and aid early identification.

• Turning A "Brick Dust" Compound Into A Clinically Viable Oral Formulation

  Advanced wet milling and particle stabilization improve solubility, enhance bioavailability, and support scalable manufacturing for complex oral drug development programs.

• Overcoming Challenges To High-Concentration Formulation Development

  Explore how the S-HiCon™ platform optimizes high-concentration therapeutic antibody formulations, overcoming stability and manufacturability challenges to deliver safe, effective therapies.

• Isolate Bright GFP-Expressing HEK293 Cells For Cell Line Development Workflow

  Explore a high-efficiency workflow for isolating and expanding GFP-expressing HEK293 cells that enables stable, bright clones ideal for imaging and tracking to simplify clonal development.

• Patented Process For Intermediates Useful For Etrasimod Arginine

  3/13/2026

  Explore how rethinking the synthetic strategy for Etrasimod can overcome the limitations of legacy routes, enabling more efficient chirality control, improved scalability, and more practical industrial API production.

• Amorphous Stability: Mesoporous Silica For Poor Glass Formers

  6/5/2025

  Discover how mesoporous silica outperforms polymeric solid dispersions in stabilizing poor glass formers, as well as how it offers a novel approach to enhance amorphous drug stability and bioavailability.

• Effect Of Column Chemistry On The Separation Of GLP-1 Peptides

  7/29/2026

  Small changes in mobile phase, temperature, and column chemistry can affect the detection of GLP-1 peptide impurities. Learn which conditions improve resolution for challenging peptide analyses.

• Integrating Phase-Appropriate Quality Standards

  12/9/2024

  Incorporating phase-specific quality standards ensures GMP compliance. Collaborating with an experienced CDMO addresses late-stage quality needs and efficiently manages development timelines.

• Quantifying Endotoxins Via Absorbance Or Fluorescence

  3/20/2026

  Find out how endotoxin assays use Factor C activation to generate measurable absorbance or fluorescence signals, with guidance on selecting detection formats and implementing scalable workflows.